Therapeutic mixture useful in inhibiting lesion formation after vascular injury
OwnerWayne H. Kaesemeyerinventor
Life of this patent
Estimating the term…
Abstract
Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.
Claims22
A method for reducing the probability of restenosis, said method comprising:
- introducing intramurally to a site of an injury, a therapeutic mixture, said therapeutic mixture including a biological equivalent of L-arginine, and an agent which enhances NO availability.
A method for reducing the probability of restenosis resulting from vascular injury, said method comprising:
- introducing intramurally proximal to the site of said injury over a predetermined time of an active agent, said active agent including a nitric oxide precursor and an Hmg-CoA reductase inhibitor.
A method for reducing the probability of restenosis resulting from injury caused by angioplasty or atherectomy, said method comprising:
- introducing to said injury a stent, said stent having a body comprised of L-arginine and a NOS agonist.
A stent having a body which includes a biological equivalent of L-arginine and an agent which enhances no production, said biological equivalent of L-arginine and agent releasable under conditions present in a blood vessel.
A local in-dwelling intra-arterial eluting drug delivery device comprised of a body, said body incorporating a therapeutic mixture therein, said therapeutic mixture including a NO precursor agent and an agent which enhances the conversion of the precursor agent to native NO.
Dependencies are inferred from the claim text.